BioArctic AB (STO:BIOAB) announced on Thursday that the company has appointed Dr. Per-Ola Freskgård to strengthen BioArctic's development of its technology platform to facilitate passage of antibodies and other biologics across the blood-brain barrier.

Reportedly, the objective of BioArctic's novel technology is to be able in the future to apply it to the company's own antibodies and also for other companies to apply it in development of their antibodies.

With the appointment of Dr Freskgård, BioArctic further strengthens its capabilities in the neuroscience therapeutic area, antibody engineering and blood-brain barrier competence.

Most recently, Dr. Freskgård was vice director, distinguished scientist and group head Neurovascular Biology at the Roche Innovation Centre in Basel, where he was responsible for the implementation of new technologies to develop biologic drugs for neurological disorders.

Prior to that, Dr. Freskgård held several positions within academia and industry, including at AstraZeneca and Novo Nordisk, with focus on developing new therapies within the central nervous system.

For the last 15 years, Dr. Freskgård has been active in research around new treatments for Alzheimer's disease and other neurodegenerative diseases. Currently, Dr. Freskgård is one of the world's leading experts on mechanisms that increase the passage of biologic drugs across the blood-brain barrier.

BioArctic is a Swedish research-based biopharmaceutical company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The company is also developing a potential treatment for Complete Spinal Cord Injury.